RT Journal Article
T1 Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.
A1 Cattrini, Carlo
A1 España, Rodrigo
A1 Mennitto, Alessia
A1 Bersanelli, Melissa
A1 Castro, Elena
A1 Olmos, David
A1 Lorente, David
A1 Gennari, Alessandra
K1 LuPSMA
K1 PARP inhibitors
K1 androgen-receptor signaling inhibitors
K1 chemotherapy
K1 ipatasertib
K1 metastatic castration-resistant prostate cancer
K1 metastatic hormone-naïve prostate cancer
K1 metastatic hormone-sensitive prostate cancer
K1 nonmetastatic castration-resistant prostate cancer
AB The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177-PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN).
SN 2072-6694
YR 2021
FD 2021-09-08
LK http://hdl.handle.net/10668/18557
UL http://hdl.handle.net/10668/18557
LA en
DS RISalud
RD Apr 4, 2025